(Q45401215)

English

Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Fukai K

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Zhang KY

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Imazeki F

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Kurihara T

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Mikata R

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Yokosuka O

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

publication date

1 September 2007

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

661-666

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Cloning and structural analyses of hepatitis B virus DNAs, subtype adr.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Identification of HBV DNA sequences that are predictive of response to lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00852.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2007.00852.X

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45401215&oldid=2076615904"